89Bio, Inc.(ETNB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ETNB 89Bio, Inc.

盘前交易 07-03 04:32:15 EDT

7.60

-0.16

-2.06%

最高7.85	最低7.41	成交量91.63万
今开7.85	昨收7.76	日振幅5.67%
总市值7.48亿	流通市值5.30亿	总股本9,838万
成交额692.21万	换手率1.31%	流通股本6,980万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ETNB","market":"US","secType":"STK","nameCN":"89Bio, Inc.","latestPrice":7.6,"timestamp":1719950400000,"preClose":7.76,"halted":0,"volume":916271,"delay":0,"floatShares":69796795,"shares":98383998,"eps":-2.016502,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.16,"latestTime":"07-03 04:32:15 EDT","open":7.85,"high":7.85,"low":7.41,"amount":6922071.891852,"amplitude":0.056701,"askPrice":8.45,"askSize":8,"bidPrice":7,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.016502,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720013400000},"adr":0,"listingDate":1573448400000,"adjPreClose":7.6,"postHourTrading":{"tag":"盘后","latestPrice":7.6,"preClose":7.6,"latestTime":"19:53 EDT","volume":18836,"amount":143179.92,"timestamp":1719964386986},"volumeRatio":0.440147845150658,"impliedVol":0.8305,"impliedVolPercentile":0.4223},"requestUrl":"/m/hq/s/ETNB","defaultTab":"news","newsList":[{"id":"2442665552","title":"89Bio, Inc.盘中异动 大幅拉升5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442665552","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442665552?lang=zh_cn&edition=full","pubTime":"2024-06-12 21:31","pubTimestamp":1718199083,"startTime":"0","endTime":"0","summary":"北京时间2024年06月12日21时31分，89Bio, Inc.股票出现波动，股价急速上涨5.18%。89Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，Avidity Biosciences, Inc.、Passage Bio, Inc.、Molecular Partners Ag涨幅较大，Tonix Pharmaceuticals Holding Corp.、Tracon Pharmaceuticals, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为36.27%、18.90%、3.57%，振幅较大的相关个股有Passage Bio, Inc.、Xortx Therapeutics Inc.、Akari Therapeutics Plc，振幅分别为21.10%、20.93%、8.28%。消息层面，截至21时31分，《H.C. Wainwright维持89bio买入评级，维持目标价29美元》资讯为影响89Bio, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213123aef49711&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240612213123aef49711&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ETNB","BK4139","BK4585"],"gpt_icon":0},{"id":"2441482270","title":"BUZZ-在礼来公司的肥胖症药物显示出对肝脏疤痕的益处后，NASH 药物开发商倒下了","url":"https://stock-news.laohu8.com/highlight/detail?id=2441482270","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441482270?lang=zh_cn&edition=full","pubTime":"2024-06-05 23:09","pubTimestamp":1717600192,"startTime":"0","endTime":"0","summary":"    6月5日 - ** NASH药物开发商Madrigal Pharmaceuticals   股价下跌约10%，报220.76美元；Akero Therapeutics   下跌3.3%，报18.58美元；89Bio   下跌约2%，报8.19美元。** 礼来  报告了其肥胖症药物的中期研究数据，该药物正在一种以前被称为NASH、现在被称为代谢功能障碍相关性脂肪性肝炎的严重脂肪肝患者中进行测试。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU2491050154.USD","LU0943347566.SGD","LU2491049909.HKD","LU1023059063.AUD","LU2491050071.SGD","LU1551013342.USD","ETNB","GB00BDT5M118.USD","LLY","LU1814569148.SGD","LU0708995401.HKD","IE00BJJMRZ35.SGD","LU1712237335.SGD","LU0122379950.USD","LU2237443622.USD","IE00B1BXHZ80.USD","LU2237443549.SGD","LU1988902786.USD","LU1551013425.SGD","LU1804176565.USD","BK4007","LU1623119135.USD","LU0061475181.USD","LU0820561909.HKD","LU0289739699.SGD","BK4534","LU0097036916.USD","LU2237443978.SGD","LU0058720904.USD","LU2264538146.SGD","LU2265009873.SGD","LU1057294990.SGD","BK4533","LU0256863811.USD","LU1280957306.USD","LU0109391861.USD","LU2237443382.USD","AKRO","IE00BJT1NW94.SGD","LU0882574055.USD","LU0882574139.USD","IE0004445239.USD","IE0009355771.USD","MDGL","LU0689472784.USD","BUZZ","LU0079474960.USD","IE0002141913.USD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2436121859","title":"坎托菲茨杰拉德公司：重申89bio(ETNB.US)评级，由增持调整至增持评级, 目标价29.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2436121859","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436121859?lang=zh_cn&edition=full","pubTime":"2024-05-17 21:56","pubTimestamp":1715954160,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司：重申89bio(ETNB.US)评级，由增持调整至增持评级, 目标价29.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405172156078774ac2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405172156078774ac2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ETNB"],"gpt_icon":0},{"id":"2435653258","title":"Evercore ISI Group：维持89bio(ETNB.US)评级，由优于大市调整至优于大市评级, 目标价由37.00美元调整至33.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2435653258","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435653258?lang=zh_cn&edition=full","pubTime":"2024-05-15 21:26","pubTimestamp":1715779564,"startTime":"0","endTime":"0","summary":"Evercore ISI Group：维持89bio(ETNB.US)评级，由优于大市调整至优于大市评级, 目标价由37.00美元调整至33.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405152126088b0b6f05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405152126088b0b6f05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ETNB","EVR"],"gpt_icon":0},{"id":"2419124937","title":"资料盒-Madrigal公司的药物在美国首次获批治疗脂肪肝NASH，竞争对手却围追堵截","url":"https://stock-news.laohu8.com/highlight/detail?id=2419124937","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2419124937?lang=zh_cn&edition=full","pubTime":"2024-03-15 04:09","pubTimestamp":1710446976,"startTime":"0","endTime":"0","summary":"    路透社3月14日 - Madrigal Pharmaceuticals公司的  药物成为第一个获得监管部门批准的 ，用于治疗一种以前被称为非酒精性脂肪性肝炎的严重类型的脂肪肝，因为开发一个数十亿美元市场的竞争正在加剧。在周四获得批准之前，该公司在开发这种疾病的治疗方法方面取得了有限的成功，这种疾病与肥胖密切相关，而且正在迅速蔓延。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2361044865.SGD","LU1712237335.SGD","LU1623119135.USD","IONS","LU1878469433.USD","LU0820561909.HKD","LLY","GB00BDT5M118.USD","LU2491049909.HKD","LU0882574055.USD","LU1066051498.USD","LU0943347566.SGD","LU1066053197.SGD","LU1804176565.USD","LU2237443549.SGD","ALT","MRK","LU2461242641.AUD","SG9999014880.SGD","BK4533","LU2361044949.HKD","SG9999015341.SGD","LU1551013342.USD","AKRO","LU2491050154.USD","LU2023250843.SGD","LU2237443622.USD","SG9999014575.USD","BK4534","LU0114720955.EUR","ETNB","MDGL","LU2491050071.SGD","LU1917777945.USD","IE00BJJMRZ35.SGD","LU2237443978.SGD","IE0002141913.USD","SG9999001176.SGD","LU1551013425.SGD","LU2264538146.SGD","SG9999014559.SGD","LU1989772923.USD","LU0097036916.USD","LU0256863811.USD","LU2265009873.SGD","LU2237443382.USD","LU0211331839.USD","VKTX","IE0009355771.USD","LU2361045086.USD"],"gpt_icon":0},{"id":"2409683285","title":"BUZZ-礼来公司的减肥药在试验中显示出前景，NASH 药物开发商业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2409683285","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409683285?lang=zh_cn&edition=full","pubTime":"2024-02-07 00:42","pubTimestamp":1707237750,"startTime":"0","endTime":"0","summary":" (更新)    2月6日 - ** 礼来公司的  减肥药 达到了脂肪肝患者中期试验的主要目标，导致开发NASH治疗药物的公司股价下跌 ** 礼来公司周二在 ，称替泽帕肽帮助73.9%的患者在52周时实现了 \"不发病 \"的目标** 非酒精性脂肪性肝炎 是脂肪肝的一种类型，目前市场上还没有批准的治疗方法。** 竞争对手Akero Therapeutics   的股价跌 至近两个月低点 15.32美元**NeuroBo Pharmaceuticals   和89bio Inc   等其他NASH药物开发商的股价分别下跌12.4%至4.38美元和23.8%至7.47美元的两个多月低点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","LU2237443382.USD","BUZZ","SG9999014906.USD","LLY","LU0882574055.USD","LU0640476718.USD","BK4585","AKRO","IE00BFTCPJ56.SGD","LU0097036916.USD","LU0820561818.USD","LU0820561909.HKD","LU0943347566.SGD","LU1551013342.USD","LU1551013425.SGD","BK4588","LU1712237335.SGD","LU2237443978.SGD","LU2491049909.HKD","SG9999014880.SGD","IE00B2B36J28.USD","IE0002141913.USD","LU2491050071.SGD","SG9999014914.USD","LU2237443549.SGD","ETNB","BK4139","LU0466842654.USD","GB00BDT5M118.USD","NRBO","IE0009355771.USD","LU0689472784.USD","LU2491050154.USD","MDGL","LU0198837287.USD","LU1064131342.USD","LU2602419157.SGD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU0320765059.SGD","LU1623119135.USD","LU2264538146.SGD","BK4534","BK4533","LU0256863811.USD","LU2237443622.USD","LU1267930730.SGD","SG9999014898.SGD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.89bio.com","stockEarnings":[{"period":"1week","weight":-0.0331},{"period":"1month","weight":-0.038},{"period":"3month","weight":-0.3008},{"period":"6month","weight":-0.3327},{"period":"1year","weight":-0.5863},{"period":"ytd","weight":-0.3196}],"compareEarnings":[{"period":"1week","weight":0.0077},{"period":"1month","weight":0.041},{"period":"3month","weight":0.057},{"period":"6month","weight":0.1749},{"period":"1year","weight":0.2371},{"period":"ytd","weight":0.1551}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"89bio, Inc.于2019年6月作为一家特拉华州公司成立，以经营2018年1月在以色列注册成立的89Bio有限公司的业务。该公司是一家临床阶段的生物制药公司，致力于开发治疗肝脏和心血管疾病的创新疗法并将其商业化。他们的主要候选产品BIO89-100是FGF21的经过特殊工程改造的糖聚乙二醇化类似物，目前正在开发中，用于治疗NASH。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.179236},{"month":2,"riseRate":0.8,"avgChangeRate":0.131113},{"month":3,"riseRate":0.4,"avgChangeRate":-0.076134},{"month":4,"riseRate":0.4,"avgChangeRate":-0.12055},{"month":5,"riseRate":0.6,"avgChangeRate":0.054165},{"month":6,"riseRate":0.6,"avgChangeRate":-0.022743},{"month":7,"riseRate":0.4,"avgChangeRate":0.04979},{"month":8,"riseRate":1,"avgChangeRate":0.19692},{"month":9,"riseRate":0.5,"avgChangeRate":-0.019034},{"month":10,"riseRate":0.25,"avgChangeRate":-0.017585},{"month":11,"riseRate":0.5,"avgChangeRate":-0.039754},{"month":12,"riseRate":0.4,"avgChangeRate":0.142591}],"exchange":"NASDAQ","name":"89Bio, Inc.","nameEN":"89Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"89Bio, Inc.(ETNB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供89Bio, Inc.(ETNB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"89Bio, Inc.,ETNB,89Bio, Inc.股票,89Bio, Inc.股票老虎,89Bio, Inc.股票老虎国际,89Bio, Inc.行情,89Bio, Inc.股票行情,89Bio, Inc.股价,89Bio, Inc.股市,89Bio, Inc.股票价格,89Bio, Inc.股票交易,89Bio, Inc.股票购买,89Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"89Bio, Inc.(ETNB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供89Bio, Inc.(ETNB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}